Balanced news tone
News Sentiment
DRUG sentiment intelligence
Bright Minds Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
46 relevant articles
Price is moving more forcefully than the current news tone suggests.
75/100 classification confidence.
directly relevant articles
high-authority source matches
+15.1% over one week, +27.7% over four weeks, trend inactive, and materially above fair value.
Understanding Momentum Shifts in (DRUG)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
75/100 classification
One-week reaction
15.1%
Price confirming higher
Trend fit
Trend inactive
27.7% over four weeks
Fair value
142.4%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
28
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Traders Daily
Direct company coverage
Understanding Momentum Shifts in (DRUG)
This article analyzes Bright Minds Biosciences Inc. (DRUG) using AI models to identify momentum shifts and provide trading strategies. Key findings indicate strong sentiment across all horizons, an 87.9:1 risk-reward setup, and several actionable trading strategies for different
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 13 Jul 2026 06:11
- Source
- Stock Traders Daily
Stock Titan
Direct company coverage
Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake
Bright Minds Biosciences Inc. CEO, Ian McDonald, has reported a 13.6% beneficial ownership stake in the company, amounting to 1,398,290 common shares as of July 2, 2026. This updated figure reflects his sole voting and dispositive power, with previous filings showing varying perc
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 21:40
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com
This article announces that BRIGHT MINDS BIOSCIENCES INC. filed a Form 13D/A on July 2nd. The content of the filing itself is not provided, but the article focuses on this specific regulatory event. It is a brief news item indicating a recent corporate action.
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 02 Jul 2026 21:40
- Source
- Investing.com Canada
Stock Traders Daily
Direct company coverage
Avoiding Lag: Real-Time Signals in (DRUG) Movement
This article provides a real-time analysis of Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting strong sentiment across all horizons and a current breakdown in price. It presents specific institutional trading strategies, including position trading, momentum breakout, an
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 02 Jul 2026 04:39
- Source
- Stock Traders Daily
simplywall.st
Direct company coverage
We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 30 Jun 2026 07:00
- Source
- simplywall.st
TradingView
Direct company coverage
DRUG Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Bright Minds Biosciences Inc. (DRUG) stock for 2027, based on analyst opinions. It details the current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also answer
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 13:41
- Source
- TradingView
TradingView
Direct company coverage
Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG)
This article provides key financial data and analyst estimates for Bright Minds Biosciences Inc. (CSE:DRUG). It details the company's stock performance, market capitalization, earnings, and revenue, alongside analyst price targets and volatility metrics. The information is presen
- Tone
- Positive 64/100
- Event
- Earnings
- Published
- 27 Jun 2026 10:39
- Source
- TradingView
Intellectia AI
Direct company coverage
DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides financial insights into Bright Minds Biosciences Inc. (DRUG), detailing its revenue streams, profitability margins, and a comparison with competitors like EPRX and PRME. While specific gross, operating, and net margins for DRUG are listed as N/A, its Return
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 22 Jun 2026 07:11
- Source
- Intellectia AI
Intellectia AI
Direct company coverage
DRUG Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Bright Minds Biosciences Inc (DRUG). It aggregates 11 technical signals, indicating a "Neutral" overall sentiment with 5 buy and 6 sell indicators. The analysis covers momentum indicators like RSI and MACD, s
- Tone
- Negative 36/100
- Event
- Guidance
- Published
- 21 Jun 2026 20:12
- Source
- Intellectia AI
Stock Traders Daily
Direct company coverage
Discipline and Rules-Based Execution in DRUG Response
This article provides an AI-generated analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies including position, momentum breakout, and risk hedging, alo
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 21 Jun 2026 03:50
- Source
- Stock Traders Daily
TradingKey
Direct company coverage
Bright Minds Biosciences Inc (DRUG) Institutional Confidence
This article from TradingKey provides an overview of Bright Minds Biosciences Inc's (DRUG) institutional confidence score, which is currently 0.00. It details the shareholdings of key institutional investors, including Janus Henderson Investors, McDonald (Ian), and Cormorant Asse
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 18 Jun 2026 12:40
- Source
- TradingKey
TradingKey
Direct company coverage
Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates
Bright Minds Biosciences Inc (DRUG) earnings forecast indicates a "Buy" trend based on 7 analysts, with a target price of USD 148.557, suggesting a 148.34% upside. The company's recent EPS was USD -0.71, exceeding the market expectation of USD -0.78, and the next quarter's EPS is
- Tone
- Positive 76/100
- Event
- Earnings
- Published
- 18 Jun 2026 12:39
- Source
- TradingKey
TradingKey
Direct company coverage
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Bright Minds Biosciences Inc (DRUG), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The overview also includes the current stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 12:39
- Source
- TradingKey
TradingKey
Direct company coverage
Bright Minds Biosciences Inc
This article provides a revenue breakdown for Bright Minds Biosciences Inc (DRUG), indicating that relevant financial data has not yet been disclosed by the company, either by business segment or by region. It also includes current stock information, showing a slight decrease in
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 00:10
- Source
- TradingKey
TradingKey
Direct company coverage
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Bright Minds Biosciences Inc (DRUG), providing lists of major shareholders by proportion and institutional holdings over several quarters. It also categorizes shareholders by type and lists the company's proportion in various rela
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 23:10
- Source
- TradingKey
Stock Traders Daily
Direct company coverage
Behavioral Patterns of DRUG and Institutional Flows
This article from Stock Traders Daily analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging,
- Tone
- Negative 41/100
- Event
- Guidance
- Published
- 10 Jun 2026 02:10
- Source
- Stock Traders Daily
The Canadian Securities Exchange (CSE)
Direct company coverage
News Releases for Bright Minds Biosciences Inc.
This page provides news releases for Bright Minds Biosciences Inc., a company listed on the Canadian Securities Exchange (CSE) under the symbol DRUG. It includes information on the company's status, industry, issued and outstanding shares, and links to various filings and news up
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jun 2026 19:39
- Source
- The Canadian Securities Exchange (CSE)
Finviz
Direct company coverage
DRUG - Bright Minds Biosciences Inc Stock Price and Quote
This article provides comprehensive financial data and news for Bright Minds Biosciences Inc. (DRUG), including its stock price, market cap, key financial ratios, and recent news events. It details analyst ratings, insider transactions, and upcoming conference presentations, offe
- Tone
- Positive 60/100
- Event
- Analyst action
- Published
- 05 Jun 2026 12:40
- Source
- Finviz
Moomoo
Direct company coverage
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145
H.C. Wainwright has reiterated its Buy rating for Bright Minds Biosciences (DRUG.US) and maintained a target price of $145. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 03 Jun 2026 00:39
- Source
- Moomoo
Stock Titan
Direct company coverage
Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates
Bright Minds Biosciences Inc. (DRUG) has announced the details for its 2026 Annual General Meeting (AGM) to be held in Vancouver on March 31, 2026. The record date for notice, voting, and beneficial ownership determination is set for February 10, 2026. The company will utilize a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 15:40
- Source
- Stock Titan
Investing.com Nigeria
Direct company coverage
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $145 price target for Bright Minds Biosciences (NASDAQ:DRUG) following positive Phase 2 clinical trial results for its drug BMB-101 in treating drug-resistant epilepsy. The stock has seen a significant increase over the past year,
- Tone
- Positive 90/100
- Event
- Analyst action
- Published
- 02 Jun 2026 11:40
- Source
- Investing.com Nigeria
TipRanks
Direct company coverage
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- TipRanks
The Globe and Mail
Direct company coverage
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight its CNS-focused drug pipeline. The company also granted 109,000 stock options to directors, officers, and consultants, aligning their interests with long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 19:10
- Source
- The Globe and Mail
Stock Traders Daily
Direct company coverage
(DRUG) Movement Within Algorithmic Entry Frameworks
This article provides an in-depth algorithmic analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting a strong near-term sentiment shifting to a long-term positive bias. It presents several AI-generated trading strategies including position trading, momentum break
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 30 May 2026 21:39
- Source
- Stock Traders Daily
GlobeNewswire
Direct company coverage
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
Bright Minds Biosciences will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT. The company also announced the grant of stock options for 109,000 common shares to directors, officers, and consultants, exercisable at US$83.40 per sha
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 27 May 2026 21:09
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk
Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. EDT, with a webcast available for 30 days. The company also granted 109,000 stock options to directors, officers, and consultants. These options are exer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event
Bright Minds Biosciences (NASDAQ: DRUG) is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 PM EDT, with a webcast available. The company also announced it granted 109,000 stock options to directors, officers, and consultants at an exerc
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 26 May 2026 23:40
- Source
- Stock Titan
TipRanks
Direct company coverage
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 May 2026 07:00
- Source
- TipRanks